TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1133, doi. 10.1007/s00262-006-0262-3
- By:
- Publication type:
- Article
Works matching IS 03407004 AND DT 2007 AND VI 56 AND IP 8
Results: 17
1
2
[F-18]-Fluoro-2-deoxy- d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1163, doi. 10.1007/s00262-006-0265-0
- By:
- Publication type:
- Article
3
Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1143, doi. 10.1007/s00262-006-0263-2
- By:
- Publication type:
- Article
4
NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1153, doi. 10.1007/s00262-006-0264-1
- By:
- Publication type:
- Article
5
Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1299, doi. 10.1007/s00262-007-0282-7
- By:
- Publication type:
- Article
6
Assessment of CD4<sup>+</sup> T cells specific for the tumor antigen SSX-1 in cancer-free individuals.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1183, doi. 10.1007/s00262-006-0269-9
- By:
- Publication type:
- Article
7
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1173, doi. 10.1007/s00262-006-0266-z
- By:
- Publication type:
- Article
8
The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1225, doi. 10.1007/s00262-006-0274-z
- By:
- Publication type:
- Article
9
Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1215, doi. 10.1007/s00262-006-0273-0
- By:
- Publication type:
- Article
10
An MVA vaccine overcomes tolerance to human p53 in mice and humans.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1193, doi. 10.1007/s00262-006-0270-3
- By:
- Publication type:
- Article
11
Efficacy of an osmotic pump delivered, GM-CSF-based tumor vaccine in the treatment of upper aerodigestive squamous cell carcinoma in rats.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1207, doi. 10.1007/s00262-006-0271-2
- By:
- Publication type:
- Article
12
Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1265, doi. 10.1007/s00262-006-0277-9
- By:
- Publication type:
- Article
13
International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1311, doi. 10.1007/s00262-007-0308-1
- By:
- Publication type:
- Article
14
Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1237, doi. 10.1007/s00262-006-0275-y
- By:
- Publication type:
- Article
15
Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1275, doi. 10.1007/s00262-006-0278-8
- By:
- Publication type:
- Article
16
Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1251, doi. 10.1007/s00262-006-0276-x
- By:
- Publication type:
- Article
17
Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity.
- Published in:
- Cancer Immunology, Immunotherapy, 2007, v. 56, n. 8, p. 1285, doi. 10.1007/s00262-007-0279-2
- By:
- Publication type:
- Article